TIL | Jotup

Obsidian Therapeutics Appoints Jeffrey Trigilio as Chief Financial Officer

Retrieved on:

月曜日, 4月 15, 2024

Biotechnology, Health, Genetics, Pharmaceutical, Oncology, Credit Suisse, Corporate finance, RBC Capital Markets, Amylyx Pharmaceuticals, Alexion Pharmaceuticals, Cornell University, TIL, Record, Columbia Business School, Therapy, Growth

Obsidian Therapeutics, Inc., a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced the appointment of Jeffrey Trigilio as Chief Financial Officer, effective May 1, 2024.

Key Points:

Obsidian Therapeutics, Inc., a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced the appointment of Jeffrey Trigilio as Chief Financial Officer, effective May 1, 2024.
“We are thrilled to welcome Jeff to the Obsidian leadership team as the company’s Chief Financial Officer,” said Madan Jagasia, M.D., Chief Executive Officer of Obsidian.
Most recently, he served as Chief Financial Officer of Cullinan Oncology, where he guided its initial public offering and helped secure several business development transactions for its portfolio.
Before Cullinan, Mr. Trigilio served as Chief Financial Officer for Amylyx Pharmaceuticals, Vice President of Corporate Finance at BlueRock Therapeutics, and in various corporate strategy and finance roles at Alexion Pharmaceuticals.

Oncolytics Biotech® Announces Upcoming Presentations at the American Society of Clinical Oncology Annual Meeting

Retrieved on:

木曜日, 4月 25, 2024

FOLFIRINOX, Abstract (summary), Abstract, Immunotherapy, Breast, TSX, AB, ONC, ASCO, TIL, Patient, Society, Annual general meeting, SAN

SAN DIEGO and CALGARY, AB, April 25, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced the acceptance of two abstracts at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, which is taking place from May 31 – June 4, 2024, in Chicago, Illinois.

Key Points:

SAN DIEGO and CALGARY, AB, April 25, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced the acceptance of two abstracts at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, which is taking place from May 31 – June 4, 2024, in Chicago, Illinois.
Details on the abstracts and poster presentation are shown below.
Title: Phase 1/2 randomized, open-label, multicenter, Simon two-stage study of pelareorep combined with modified FOLFIRINOX +/- atezolizumab in patients with metastatic pancreatic ductal adenocarcinoma.
Abstracts will be published on the ASCO Annual Meeting website at 5:00 p.m.

Oncolytics Biotech® Announces Upcoming Presentations at the American Society of Clinical Oncology Annual Meeting

Retrieved on:

木曜日, 4月 25, 2024

FOLFIRINOX, Abstract (summary), Abstract, Immunotherapy, Breast, TSX, AB, ONC, ASCO, TIL, Patient, Society, Annual general meeting, SAN

SAN DIEGO and CALGARY, AB, April 25, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced the acceptance of two abstracts at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, which is taking place from May 31 – June 4, 2024, in Chicago, Illinois.

Key Points:

SAN DIEGO and CALGARY, AB, April 25, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced the acceptance of two abstracts at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, which is taking place from May 31 – June 4, 2024, in Chicago, Illinois.
Details on the abstracts and poster presentation are shown below.
Title: Phase 1/2 randomized, open-label, multicenter, Simon two-stage study of pelareorep combined with modified FOLFIRINOX +/- atezolizumab in patients with metastatic pancreatic ductal adenocarcinoma.
Abstracts will be published on the ASCO Annual Meeting website at 5:00 p.m.

Achilles Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Business Highlights

Retrieved on:

木曜日, 4月 4, 2024

Research, Virtual, NSCLC, Immunotherapy, TIL, Patient, G&A, Allele, ACHL, HLA, Neoplasm, Therapy, Event, Safety, Melanoma, Patent, Escape Room, Cryptocurrency

LONDON, April 04, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today announced its financial results for the fourth quarter and year-ended December 31, 2023, and recent business highlights.

Key Points:

These learnings will inform the development of cNeT and related neoantigen vaccine and TCR-T therapies,” said Dr Iraj Ali, Chief Executive Officer of Achilles Therapeutics.
Research and development (R&D) expenses: R&D expenses were $15.9 million for the fourth quarter ended December 31, 2023, a decrease of $3.0 million compared to $18.9 million for the fourth quarter ended December 31, 2022.
General and administrative (G&A) expenses: G&A expenses were $3.6 million for the fourth quarter ended December 31, 2023, a decrease of $0.4 million compared to $4.0 million for December 31, 2022.
Net loss: Net loss for the fourth quarter ended December 31, 2023 was $18.6 million or $0.46 per share compared to $24.1 million or $0.61 per share for the fourth quarter ended December 31, 2022.

Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning

Retrieved on:

木曜日, 4月 4, 2024

Lymphocytopenia, Neutropenia, NSCLC, TIL, Patient, ACHL, Therapy, Safety, Melanoma, Blood, Escape Room

LONDON, April 04, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today announced interim Phase I/IIa data on the use of clonal neoantigen reactive T cells (cNeT) from the CHIRON study in advanced unresectable or metastatic non-small cell lung cancer (NSCLC) and the THETIS study in recurrent or metastatic malignant melanoma. The update includes data from 18 patients across CHIRON (n=12) and THETIS (n=6) dosed since the previous interim update in December 2022, with two CHIRON patients and one THETIS patient having received enhanced chemo-conditioning and IL-2 dosing aligned to standard tumor infiltrating lymphocyte (TIL) therapy (enhanced host conditioning) in a new Cohort C. This new Cohort C will allow the impact of enhanced host conditioning on cNeT engraftment and persistence beyond 28 days to be evaluated.

Key Points:

All trial participants were late-stage, checkpoint refractory patients with progressive disease at the time of lymphodepletion.
The observed tolerability profiles remain favorable and similar to standard TIL therapy.
These learnings will inform the development of cNeT and related neoantigen vaccine and TCR-T therapies,” said Dr Iraj Ali, CEO of Achilles Therapeutics.
“We have made important progress in the optimization of our VELOS manufacturing process with a significant improvement in cNeT doses delivered and are developing our understanding of the relationship between host conditioning and the engraftment of infused cNeT.

Phio Pharmaceuticals Reports 2023 Year End Financial Results and Provides Business Update

Retrieved on:

火曜日, 4月 2, 2024

MARLBOROUGH, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today reported its financial results for the year ended December 31, 2023 and provided a business update.

Key Points:

The latter clearance was significant since there are no drugs specifically approved to treat early stages I and II of cSCC.
As of February, the first two patients in our first cohort have completed treatment with PH-762 with no reported adverse events.
In 2023 we implemented a cost rationalization program driven by our transition from discovery research to product development.
At December 31, 2023 we had cash of $8.5 million as compared with $11.8 million at December 31, 2022.

Obsidian Therapeutics Presents Positive 25-Week Median Study Follow-Up Safety and Efficacy Data from First-in-Human Study of OBX-115 in Advanced Melanoma at the American Association for Cancer Research Annual Meeting

Retrieved on:

火曜日, 4月 9, 2024

, professor of Melanoma Medical Oncology at The University of Texas MD Anderson Cancer Center and principal investigator of the study.

Key Points:

, professor of Melanoma Medical Oncology at The University of Texas MD Anderson Cancer Center and principal investigator of the study.
The single-center study ( NCT05470283 ) is evaluating the safety, tolerability, dosing, and efficacy of OBX-115 in patients with ICI-resistant metastatic melanoma.
All 6 patients had disease that was primary-resistant to anti–PD-1 therapy, with a median of 2.5 (range, 1–5) lines of prior therapy.
In addition to the first-in-human study, Obsidian is actively enrolling patients with metastatic melanoma and NSCLC at multiple sites in its ongoing Phase 1/2 multicenter study.

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Retrieved on:

金曜日, 3月 22, 2024

Date, Patient, SAN, Cancer, Employment, TIL

SAN CARLOS, Calif., March 22, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that on March 22, 2024 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 97,700 shares of Iovance’s common stock to twenty new, non-executive employees.

Key Points:

SAN CARLOS, Calif., March 22, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that on March 22, 2024 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 97,700 shares of Iovance’s common stock to twenty new, non-executive employees.
The awards were granted under Iovance’s 2021 Inducement Plan, which was adopted on September 22, 2021 and amended on January 12, 2022 and May 10, 2023, and provides for the granting of equity awards to new employees of Iovance by the Company’s compensation committee in accordance with Nasdaq Listing Rule 5635(c)(4).
Each of the stock options granted as referenced in this press release has an exercise price of $15.02, the closing price of Iovance’s common stock on the Date of Grant.
Each stock option vests over a three-year period, with one-third of the shares vesting on the first anniversary of the employee’s start date (the “First Vesting Date”), and the remaining shares vesting in eight quarterly installments over the next two years, commencing with the first quarter following the First Vesting Date, subject to continued employment with the Company through the applicable vesting dates.

Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Recent Business Highlights

Retrieved on:

木曜日, 3月 21, 2024

SAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided recent business highlights.

Key Points:

“2023 marked a transformative year for Turnstone Biologics in which we transitioned into a publicly traded company and continued to advance our pipeline through clinical development.
Recently, Turnstone expanded their trials to evaluate additional solid tumor types in addition to the existing indications of breast cancer and uveal melanoma.
Preclinical Data Presentations at the 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting Support Ongoing Clinical and Preclinical Efforts.
Cash, Cash Equivalents and Short-Term Investments: As of December 31, 2023, cash, cash equivalents and short-term investments were $94.8 million.

Obsidian Therapeutics Announces Oversubscribed $160.5 Million Series C Financing to Drive OBX-115 Clinical Development

Retrieved on:

水曜日, 4月 3, 2024

Obsidian Therapeutics, Inc. , a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced it has closed a significantly oversubscribed $160.5 million Series C financing with a top-tier syndicate of life science investors led by new investor, Wellington Management.

Key Points:

Obsidian Therapeutics, Inc. , a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced it has closed a significantly oversubscribed $160.5 million Series C financing with a top-tier syndicate of life science investors led by new investor, Wellington Management.
Proceeds from the financing will advance Obsidian’s lead engineered tumor-infiltrating lymphocyte (TIL) program, OBX-115, in its ongoing trials for patients with melanoma and non-small cell lung cancer (NSCLC).
The Company is focused on enrolling patients and reaching key clinical and regulatory milestones, as well as manufacturing scale-up ahead of pivotal trial readiness.
“This financing provides funding through key clinical readouts in melanoma and is the catalyst to continue expanding OBX-115 into NSCLC, where there is significant potential and high unmet need.”